Formulation and Evaluation of Venlafaxine Sustained-Release Tablets for Improved Patient Compliance: A Comprehensive Review

Abstract

The prevalence of major depressive disorder and anxiety disorders has highlighted the need for more effective and patient-friendly therapeutic approaches. Among these, Venlafaxine, a serotonin-nor epinephrine reuptake inhibitor (SNRI), is an often prescribed medication. However, its twice-daily dosage regimen can be inconvenient, leading to non-compliance. To address this issue, the development of sustained-release formulations of Venlafaxine is becoming increasingly relevant. This review paper comprehensively discusses the formulation and evaluation of Venlafaxine sustained-release tablets, with an emphasis on how this approach may enhance patient compliance.